Michael D Kluger
Overview
Explore the profile of Michael D Kluger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
88
Citations
1202
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van der Pol C, Sabil M, Komar M, Ruo L, Silva J, Mbuagbaw L, et al.
AJR Am J Roentgenol
. 2025 Mar;
PMID: 40042924
A number of patients with periampullary carcinoma deemed resectable on preoperative CT have their curative-intent surgery aborted on the basis of intraoperative findings. This study sought to identify imaging and...
2.
Martin 2nd R, White R, Bilimoria M, Kluger M, Iannitti D, Polanco P, et al.
Cancers (Basel)
. 2024 Dec;
16(23).
PMID: 39682087
Background/objectives: Overall survival for patients with Stage 3 pancreatic ductal adenocarcinoma (PDAC) remains limited, with a median survival of 12 to 15 months. Irreversible electroporation (IRE) is a local tumor...
3.
Wasko U, Jiang J, Dalton T, Curiel-Garcia A, Edwards A, Wang Y, et al.
Nature
. 2024 Nov;
635(8040):E12.
PMID: 39533066
No abstract available.
4.
Thomas A, Tehranifar P, Kwon W, Shridhar N, Sugahara K, Schrope B, et al.
J Surg Oncol
. 2024 Sep;
130(8):1589-1604.
PMID: 39348434
Introduction: Current guidelines for treatment for locally advanced pancreatic cancer recommend chemotherapy ± radiation, or radiation alone when multimodal therapy is contraindicated. In a subset of patients, guideline-recommended treatment (GRT)...
5.
Wasko U, Jiang J, Dalton T, Curiel-Garcia A, Edwards A, Wang Y, et al.
Nature
. 2024 Apr;
629(8013):927-936.
PMID: 38588697
Broad-spectrum RAS inhibition has the potential to benefit roughly a quarter of human patients with cancer whose tumours are driven by RAS mutations. RMC-7977 is a highly selective inhibitor of...
6.
Jung H, Lee M, Han Y, Thomas A, Yun W, Cho Y, et al.
HPB (Oxford)
. 2023 Dec;
26(3):400-409.
PMID: 38114399
Background: Invasive carcinomas arising from premalignant lesions are currently staged by the same criteria as conventional pancreatic ductal adenocarcinoma. Methods: Clinicopathologic information and survival data were extracted through a thorough...
7.
Wasko U, Jiang J, Curiel-Garcia A, Wang Y, Lee B, Orlen M, et al.
bioRxiv
. 2023 Dec;
PMID: 38105998
Broad-spectrum RAS inhibition holds the potential to benefit roughly a quarter of human cancer patients whose tumors are driven by RAS mutations. However, the impact of inhibiting RAS functions in...
8.
Lee M, Thomas A, Lee S, Cho Y, Jung H, Yun W, et al.
J Gastrointest Surg
. 2023 Oct;
27(11):2484-2492.
PMID: 37848688
Purpose: Although the concept of extrapancreatic extension (EPEx) was removed in the eighth edition of the American Joint Committee on Cancer pancreatic cancer staging system, several studies have supported the...
9.
Irajizad E, Kenney A, Tang T, Vykoukal J, Wu R, Murage E, et al.
Cell Rep Med
. 2023 Sep;
4(9):101194.
PMID: 37729870
Emerging evidence implicates microbiome involvement in the development of pancreatic cancer (PaCa). Here, we investigate whether increases in circulating microbial-related metabolites associate with PaCa risk by applying metabolomics profiling to...
10.
Schleimer L, Chabot J, Kluger M
Gastrointest Endosc Clin N Am
. 2023 May;
33(3):655-677.
PMID: 37245941
Historically, the management of pancreatic cystic neoplasms (PCN) has been operative. Early intervention for premalignant lesions, including intraductal papillary mucinous neoplasms (IPMN) and mucinous cystic neoplasms (MCN), offers an opportunity...